FluidAI Medical has announced the acquisition of Emmetros Limited the company behind the patient-engagement platform SparxConnect. The deal is aimed at enhancing FluidAI’s own AI-powered patient education and engagement solution, Stream Inara™, which becomes part of FluidAI’s broader surgical-care suite known as the RISE Program. The RISE (Recovery Intelligence and Surgical Excellence) Program already includes the AI-driven surgical decision-support suite Stream Care™, the FDA-cleared real-time postoperative monitoring device Origin™, and clinical documentation tool Stream CMx™.
Also Read: QIAGEN Unveils QIAsymphony Connect and Expands Precision Oncology Portfolio
By integrating SparxConnect’s patient-centric, customizable engagement capabilities, FluidAI aims to extend care beyond hospital discharge enabling pre-surgery preparation, post-surgery education, continuous engagement, and 24/7 support to ensure improved adherence to care plans and safer recoveries. The acquisition is described by Emmetros CEO & Co-Founder Mary Pat Hinton as “the best possible next chapter for our technology and our mission,” pointing to a shared commitment toward improving surgical patient outcomes. FluidAI CEO Youssef Helwa emphasized that the deal supports the company’s mission of “redefining the standard of surgical care to improve patient outcomes during recovery for safer early discharge after general and gastrointestinal surgery.” With this being FluidAI’s second acquisition after Medsix, the move underscores an acquisition-driven growth strategy designed to fortify the company’s product portfolio and expand its footprint in AI-powered surgical and postoperative care.
